home > ebr

European Biopharmaceutical Review


European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:


David Hirsh



Emma Naks

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.

View the
digital version
of EBR

Featured in this issue
In Brief

A Banner Year for Biopharma

Industry advisor Emile Bellott reflects on biopharma’s recent highs, praising the successes of 2014 and thinking ahead to what the coming months – and following years – may bring.
Genetically Engineered ADCs

Making Sense From Nonsense

Feng Tian at Ambrx examines how site-specific ADC technologies offer a new starting point for the rational design of drugs with optimised therapeutic windows. In particular, genetically engineered ADCs are well-positioned to improve targeted drug delivery.
  BioDevelopment and Regulatory
Regulatory Spotlight

Western Influence

Despite following the EMA’s lead and adopting a stepwise comparability approach, Nick Beckett and Jane Lin at CMS believe that China still has some way to go before its biosimilar regulations can be brought in line with international practice.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October
Banner of Wickham Labs on Samedan
Banner of Samedan app.EBR on Samedan
Industry Events

Orphan Drugs and Rare Diseases

19-20 October 2015, Holiday Inn Regent Park Hotel, London, UK

Returning for its 4th year and following on from the major success of previous events, SMi is proud to announce that registration is now live for the Orphan Drugs and Rare Diseases Conference taking place on 19th – 20th October 2015 in London, UK.
More info >>

News and Press Releases

CRF Health Introduces eCOA Solution for Oncology

The TrialMax® electronic Clinical Outcome Assessment (eCOA) solution, aimed specifically at oncology clinical trials, has been introduced by CRF Health.
More info >>

Banner of Genome Editing Applications on Samedan
air transport logo


White Papers

Trial Timelines

Thomson Reuters

Save resources with accurate trial length projections. How analytics based on curated content can deliver insight for clinical strategies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement